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Abstract
Purpose This article provides a review of the transcriptomic
expression profiling studies that have been performed on
meningiomas so far. We discuss some future prospects and
challenges ahead in the field of gene expression profiling.
Methods We performed a systematic search in the PubMed
and EMBASE databases in May 2010 using the following
search terms alone or in combination: “meningioma”,
“microarray analysis”, “oligonucleotide array sequence
analysis”, or “gene expression profiling”. Only original
research articles in English that had used RNA hybridized
to high-resolution microarray chips to generate gene
expression profiles were included.
Results We identified 13 articles matching the inclusion
criteria. All studies had been performed during the last decade.
Conclusions The main results of the studies can be grouped
in three categories: (1) several groups have identified
meningioma-specific genes and genes associated with the
three WHO grades, and the main histological subtypes of
grade I meningiomas; (2) one publication has shown that
the general transcription profile of samples of all WHO
grades differs in vivo and in vitro; (3) one report provides
evidence that microarray technology can be used in an
automated fashion to classify tumors. Due to lack of
consensus on how microarray data are presented, possible
general trends found across the studies are difficult to
extract. This could obstruct the discovery of important
genes and pathways universally involved in meningioma
biology.
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Introduction
Medicine has been transformed by the genomic revolution,
and classical population risk assessment and empirical
treatment challenged by molecular classification and the
concept of personalized therapy [1]. With high-throughput
molecular genetic analyses, genes and pathways associated
with, e.g., clinical progression, response to irradiation or
drugs, and environmental exposure, can be discovered [2].
Thus, new biomarkers and therapeutic targets may be
developed. During the last decade, microarray technology
has been implemented in molecular biological laboratories
world-wide, and numerous studies have been performed in
a wide range of human tissues and conditions.
Microarray chips of the size of histology slides including
all known human genes are currently manufactured with
high precision. The main methods for the production of
such chips are based on robotic spotting of cDNA probes or
oligonucleotides to a surface [3] (Fig. 1). By labeling the
RNA in the samples at study and hybridization to the
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corresponding gene probes on the microarray chip it is
subsequently possible to measure the abundance of every
gene expressed at time of tissue sampling. The measured
signals are then converted to numerical values and
interpreted with bioinformatic tools to produce the gene
expression profile.
Meningiomas (Fig. 2), being the second most common
intracranial neoplasm (20–30% of all cases) [4], have been
extensively studied in the past. An important contribution
to the understanding of the pathogenesis was the identifi-
cation of the NF2 gene located on chromosome 22q12.2
[5–8]. Loss of one allele of this gene is causing the
autosomal dominant syndrome neurofibromatosis type 2, in
which bilateral vestibular schwannomas are pathognomon-
ic, and multiple meningiomas often develop. From research
on sporadic (non-NF2-related) meningiomas it has been
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Fig. 1 Principle behind micro-
array analysis (Human Genome
Microarray, Applied Biosystems).
mRNA extracted from a biologi-
cal sample is labeled and
converted into cDNA. On a
microarray slide (“chip”),
thousands of oligonucleotides
representing individual genes
are positioned in predefined
positions. If the corresponding
cDNA is present, it will hybridize
to the oligonucleotide. By a
chemiluminescent reaction,
the presence of cDNA can
be measured
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found that loss of heterozygosity is found in 40–70% of
cases and mutations in the remaining allele present in 60%
[9–12]. Thus, a main mechanism of meningioma initiation
follows the pattern of Knudsons two-hit hypothesis: first, a
risk allele is deleted, and then a mutation in the remaining
allele containing a tumor suppressor gene initiates neoplas-
tic growth [13]. However, it follows that this mechanism is
not uniformly causing meningiomas, and that other genes
or pathways are contributing to the tumorigenesis. Hence,
gene expression profiling studies have the potential to
discover novel genes and signaling pathways with a role in
meningioma biology.
The aim behind this article is to provide a review of the
mRNA microarray studies that have been performed on
meningiomas, and to reflect the advances in the biological
understanding of the tumors gained by this technology. We
also address some future prospects and challenges ahead in
the field of gene expression profiling.
Material and methods
We performed a systematic search in the PubMed and
EMBASE databases in May 2010 with the following medical
subject headings (MeSH) terms: “meningioma”, “microarray
analysis”, “oligonucleotide array sequence analysis”, “gene
expression profiling” (Table 1). Upon literature review only
original research articles in English that had used RNA
hybridized to high-resolution microarray chips to generate
gene expression profiles were included.
Results
Based on our search criteria we detected a total of 70 studies.
There were no additional studies found in EMBASE to those
located in PubMed. All microarray studies found by search
term 1were also found with search term 3.With search term 2,
one additional study was identified; however, it was excluded
since it was a review article. With search term 3, we found one
additional RNA-based microarray study that was included.
However, many of the studies were based on quantitative
reverse transcriptase real time polymerase chain reaction
(qRT-PCR) for selected genes with an a priori hypothesis.
Other excluded studies were proteomic profiling projects,
tissue arrays, review articles, and non-human material. We
identified 13 original research articles that analyzed meningi-
oma RNA with microarray chip technology (Table 2). All
studies have been performed during the last decade.
Microarray platforms
Six different microarray platforms had been used in the
studies, with technology from Affymetrix being most fre-
quently used (eight of 13 studies). Three of the studies used
chips that were spotted with cDNA clones; the remaining used
Fig. 2 Radiological appearances of meningiomas. a Magnetic
resonance imaging (MRI) showing a large convexity meningioma
with edema and displacement of the midline to the anatomical left. b
MRI section illustrating a WHO grade I convexity meningioma
invading the frontal bone. c Large meningioma arising in the
cerebello-pontine angle compressing the brain stem. d Computerized
tomography showing multiple meningiomas and postoperative
changes in a patient with neurofibromatosis type 2
Table 1 Search terms used to identify RNA microarray studies performed on human meningioma samples in the PubMed (http://www.ncbi.nlm.
nih.gov/) and EMBASE (http://www.embase.com/) databases
Search term no. Search term PubMed hits EMBASE hits
1 “Meningioma and microarray analysis” 44 14
2 “Meningioma and oligonucleotide array sequence analysis” 37 0
3 “Meningioma and gene expression profiling” 70 27
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oligonucleotide microarrays. A high number of transcripts
were represented on the chips; however, some of the early
works included relatively few gene probes due to technical
limitations at the time of study.
Meningioma subtypes
Altogether, 227 meningiomas were included in the studies;
according to the WHO classification these were 151
grade I, 42 grade II, and 34 grade III. Some papers did
not describe the histological subtypes present in their
material; however, from the studies with histology data
available we found the following subtypes present among
the grade I tumors: fibrous (n=31), meningothelial (48),
transitional (n=27), secretory (n=1), and psammomatous
(n=1). Apart from two cases of clear cell meningiomas
(WHO grade II), there was no further information on
histological subtype for the grades II and III cases.
Source of control tissue
The aims of the various studies are different, and thus the
source of control tissue is variable. For those studies aiming
at detecting gene expression profiles separating meningio-
mas from tissue of origin the authors have extracted RNA
from meninges, dura, arachnoid cyst membranes, normal
brain, pooled normal tissue from various sources, and other
brain tumors. Other studies have aimed at detecting gene
expression changes due to irradiation, anatomical location
(spinal vs. intracranial), and WHO grade; hence, samples
from each of the categories have been compared with no
external controls applied.
Statistics
Of the 13 microarray studies, ten provided a clear
description of statistical procedure for the detection of
differentially expressed genes between cases. Most fre-
quently the Student’s t test was applied (seven studies), two
studies used the Mann–Whitney test, one study used
significance analysis of microarrays (SAM), and finally
one study used receiver operating characteristic curve.
Summary of main results (Table 2)
In the pioneering oligonucleotide microarray study on
meningiomas by Watson and colleagues [14], 15 meningio-
mas (WHO grade I, n=6; WHO grade II, n=6; WHO
grade III, n=3) and three post mortem leptomeninges were
studied. The main result was the detection of gene
expression profiles associated with WHO grade subtypes
(growth hormone receptors, endothelin receptor A, IGF2,
IGFBP-7). Selected genes were confirmed using qRT-PCR.Ta
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Sasaki and colleagues [15] aimed at comparing the
transcriptomic profiles of original meningiomas (n=3; one
of each WHO grade) and primary cultures of the same
samples. They found that 51 genes were up-regulated>
fivefold, and 19 genes were down-regulated by twofold or
more in the primary cultures. The results were validated
with qRT-PCR.
Fathallah-Shaykh and colleagues [16] studied ten menin-
giomas and compared them with pooled post mortem brain
RNA from the occipital lobes of four individuals. With their
approach 364 genes were differentially expressed, and they
found evidence of activation of different signaling pathways
like Wnt, MAP kinase, PI3K, and notch. No validation of
the findings with alternative approaches was performed.
In a study of 30 meningiomas (WHO grade I, n=13; WHO
grade II, n=12; WHO grade III, n=5) Wrobel and colleagues
[17] investigated 2,600 genes using cDNA microarrays. The
gene expression profiles of each category were compared with
each other. The main finding was that 37 genes were
decreased and 27 increases in grades II and II meningiomas
compared with grade I. Compared with a pool of RNA from
various human tissues (heart, spleen, placenta, kidney, skeletal
muscle, liver, brain, and lung) a gene signature of the
meningiomas was identified: PTGDS, CLU, BAD, MGP,
LIG1, ANXA2, MMP12, VIM, TIMP1, and CCND1 were
highly expressed in the meningiomas. Selected genes were
validated with qRT-PCR, and for several candidates the results
corroborated with those found by microarray. The authors
concluded that the study showed that genes related to cell
cycle regulation, cellular proliferation, as well as the IGF and
WNT signaling pathways were up-regulated in grades II and
III meningiomas. However, a main limitation of the study was
the low number of cDNA probes, covering <10% of all
human genes.
The aim of the study of Lusis et al. [18] was to identify
genetic events responsible for malignant progression of
meningiomas. Using the Affymetrix U133A/B GeneChip
Microarrays the authors searched for transcripts that were lost
in grade III meningiomas compared with grade I. They found
that approximately 40% of down-regulated genes in grade III
meningiomas were located at chromosomes 1p and 14q. One
of the candidates, the NDRG2 genes, was consistently down-
regulated in all grade III meningiomas both at the mRNA
and protein level, and that this was correlated with hyper-
methylation of the corresponding promoter.
As a part of a larger study of the genomics of spinal
meningiomas Sayagues et al. [19] performed gene expression
profiling to compare spinal and intracranial meningiomas.
They included seven spinal and 11 intracranial meningiomas
in the study. The main result was differential expression of
1,555 genes, of which 35 genes showed the highest
correlation (r2>0.7 or r2<−0.7). Thirty of these had lower
expression in the intracranial tumors, whereas the remaining
five genes were up-regulated. Three genes were selected for
qRT-PCR validation, and a significant correlation (p<0.001)
with microarray expression was found for all genes (NR4A3,
DUSP5, and HOXA5).
In the study of Carvalho et al. [20] the purpose was to
identify molecular signatures that characterize the different
grades of meningiomas and molecular mechanisms driving
meningioma tumorigenesis. They included 23 meningiomas
(WHO grade I, n=8; WHO grade II, n=7; WHO grade III,
n=8). Using SAM, the authors found 28 genes differential-
ly expressed between grades I and II meningiomas, and no
differential expression between grades II and III. A total of
1,212 genes were differentially expressed between grades I
and III meningiomas. In an unbiased unsupervised cluster
analysis the 23 meningiomas grouped in two branches. All
grades I and grade III meningiomas were located in
separate branches, and the authors thus designated each
branch as “low proliferative” and “high proliferative”,
respectively. The grade II meningiomas were located in
both branches, three of seven in the low-proliferative group,
and the remaining four in the high-proliferative group. A
selection of genes were validated using qRT-PCR.
In 2008, our group [21] published a microarray study on
meningiomas of grades I (n=22) and II (n=5), where the aim
was to study the gene expression profiles of meningiomas in
comparison to progenitor meningioma tissue (arachnoid
cells). Unsupervised cluster analysis of a filtered data set of
16,430 genes showed that five of seven fibrous meningiomas
clustered together, while the remaining samples (meningo-
thelial, transitional, and atypical) made no clear branching. As
control tissue we used samples from the membranes of four
arachnoid cysts (AC), and all these samples formed a separate
cluster indicating a very homogeneous transcription profile.
Using the t test, we detected 20 genes that differentiated
between meningiomas and ACs (p<4.3×10−7), in which the
tumor suppressor gene WWOX was down-regulated and the
oncogene TYMS was up-regulated. We also found 20 genes
separating fibrous from meningothelial meningiomas (p<
1.1×10−5), where DMD and BMPR1B were up-regulated in
the fibrous, and RAMP1 was down-regulated in the
meningothelial meningiomas. qRT-PCR was performed on a
selection of genes and showed similar expression profiles as
those generated using microarray analysis.
Since a recognized mechanism of meningioma initiation is
irradiation, Lillehei et al. [22] performed a microarray study of
five radiation-induced meningiomas (RIM) and six spontane-
ous meningiomas to find unique genes behind this phenom-
enon. Interestingly, based on a microarray of 54,675 genes
unsupervised hierarchical cluster analysis did not show
separate clustering of RIMs and spontaneous meningiomas.
Using a t test to compare the gene expression profiles of RIMs
and spontaneous meningiomas the authors found a small
subset of 20 genes separating the two groups (p<0.001).
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Hankins et al. [23] studied the expression profiles of
12,000 genes in six meningiomas (WHO grade I) and four
dural samples. By this approach, the authors found five up-
regulated and 35 down-regulated genes in the meningio-
mas. The down-regulation of the DLC1 gene was con-
firmed with qRT-PCR and immunohistochemical staining.
No evidence of CpG methylation of the corresponding
promoter was found. The authors concluded that DLC1
may function as a tumor suppressor gene in meningiomas.
Claus and colleagues [24] studied 31 samples from sporadic
meningiomas (WHO grade I, n=25; WHO grade II, n=6)
with the aim of examining the gene expression profiles in
relation to hormone receptor status. Estrogen receptor positiv-
ity was present in 33% and progesterone receptor positivity in
84%. In a comparison of PR+ and PR− meningiomas, the
study showed up-regulation of ten genes, and down-regulation
of 14 genes. No genes separated ER+ from ER− meningio-
mas. As the number of candidate genes was small, no single
pathways or groups of genes were clearly identified.
In 2009, Fèvre-Montange and colleagues [25] published a
transcriptomic study of 17 meningiomas (WHO grade I, n=
10; WHO grade II, n=5; WHO grade III, n=2). As control
tissue RNA from a human whole brain (72 years of age) was
used. The aim was to distinguish between the different WHO
grades and histopathological subtypes, and to identify factors
predicating recurrence. Unsupervised cluster analysis showed
three groups of samples: group A consisted of seven of ten
grade I cases, group B of the remaining three grade I samples
and all five grade II meningiomas, and finally group C
consisted of the two grade III tumors. Statistical analysis
revealed that 346 and 2,995 genes showed more than twofold
over-expression in groups B and C, respectively. Similarly,
184 and 1,380 genes were down-regulated, respectively.
Furthermore, the study showed differential gene expression
between fibrous and meningothelial meningiomas, with 12
up-regulated and 20 down-regulated genes in the fibrous
subset. Selected genes were validated with qRT-PCR.
The last published microarray study onmeningiomas so far
was published in 2009 and performed by Castells et al. [26].
The aim was to assess whether automated categorization of
brain tumors can be made by the use of microarray. Biopsies
from 35 patients (17 glioblastomas and 18 meningothelial
meningiomas) were subjected to cDNA-based microarray
analysis. The study showed up to 100% prediction accuracy
by using microarrays, thus providing evidence of possible
clinical diagnostic use of this technology.
Discussion
During the last decade, a total of 13 microarray-based studies
have been performed on RNA from altogether 227 meningio-
mas. The aims, sources of control tissue, microarray platforms,
and statistical approaches vary between the studies. The main
results of the studies can be grouped in three categories: (1)
several groups have identified meningioma-specific genes, and
genes associated with the three WHO grades and the main
histological subtypes of grade I meningiomas. (2) One
publication has shown that the general transcription profile of
samples of all WHO grades differs in vivo and in vitro. (3) One
report provides evidence that microarray technology can be
used in an automated fashion to classify tumors.
We found no clear overlap between the studies regarding
individual candidate genes. Other than the gross signature
differences identified in the studies, we were not able to detect
any shared deregulated genes. This illustrates a big challenge
in gene expression profiling studies: the vast number of
transcripts present on the chips makes it very difficult to
compare the studies and isolate key candidate genes with a
possible role in the biology. Critiques may regard this as a
weakness of the technology; however, the lack of external
validity may in fact be explained by the variation in micro-
array platforms, study populations, chip manufacturer, statis-
tical approach, and quality of RNA in the tissue at study. In
fact, the Microarray Quality Control (MAQC) project
(http://www.fda.gov/ScienceResearch/BioinformaticsTools/
MicroarrayQualityControlProject/default.htm) has shown
that the microarray quality at present may be higher than
that of, e.g., immunohistochemical analysis [27, 28]. So the
question is how should we perform microarray studies?
Would it be appropriate to standardize some factors, like the
source of control tissue and statistical procedure? And should
it be mandatory to post microarray data in publicly available
databases so that independent researchers could perform
meta-analyses with the aim of identifying biological markers
that could be used clinically? If so, would it be reasonable to
demand posting of certain data, e.g., the overall best
candidate genes for comparison purposes? Some journals
have implemented this policy, however it is our opinion that
it should be adopted globally.
To draw firmer conclusions of the studies, consensus on
source of control tissue and statistical approach, as well as
replication of the most biological relevant findings so far is
required. The time is therefore now due for a large replication
study that includes the most significant and biologically
relevant candidate genes generated from the various transcrip-
tion studies that have been performed. This means that a
custom-made microarray chip that includes these consensus
genes should be designed, and quality controlled samples
from several laboratories included. The data should also be
compared with clinical outcome in order to identify clinically
relevant genes. Recently, The Cancer Genome Atlas Research
Network successfully applied this method to a large panel of
glioblastomas [29]. Here, 206 glioblastomas were subjected
to gene expression profiling, DNA copy number variation
analysis, and CpG methylation status assessment of 601
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selected genes. It follows that such a project demands
considerable dedication, coordination, and financial support.
An interesting result was the difference in transcriptional
profiles between original frozen specimens and primary
culture of all three WHO grades. The study provides evidence
that as tumors are removed from their native environment, the
gene expression changes accordingly. Thus, results gained
from cell culture experiments have to be interpreted with
caution. Validation in vivo seems to be mandatory before firm
conclusion can be made. It is however no surprise that the
gene expression profile is altered when a tumor is removed
from its site of origin. The dynamic transcriptome will rapidly
adjust to changes in local environment to provide the
substrates necessary to maintain the tumor.
Medicine has been transformed by the genomic revolution,
and classical population risk assessment and empirical
treatment has been challenged by molecular classification
and prospects of individualized therapy [1]. With the help of
microarray technology novel candidate genes, pathways, and
networks may be linked with clinical scenarios, such as
treatment response or environmental exposure. Thus, micro-
arrays may be helpful in identifying biomarkers, developing
new treatment strategies, and in tumor classification [2]
(Fig. 3). Hence, a reasonable application of global gene
expression profiling in oncology is to subclassify brain tumors
of WHO grade II. Such tumors are generally infiltrative, have
low-proliferative activity, tend to recur, and can undergo
malignant transformation. Often there is marked clinical and
Conventional
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Fig. 3 Outline of possible
application of microarray
technology in the diagnostic
armamentarium
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morphological heterogeneity within tumors of this grade.
Thus, the categorization of grade II tumors may be more
challenging than that of purely benign or malignant entities.
With microarray analysis, high- or low-proliferative gene
expression signatures, or hyper- or hypo-mutator phenotypes
may be revealed. Consequently, signatures indicating high or
low risk of recurrence or transformation may be found. Such
information may be useful when the addition of adjuvant
therapy or follow-up schedule is discussed.
However, some technical issues make the use of this
powerful technology difficult: (1) Since only minute amounts
of RNA are required and probes corresponding to all known
genes are analyzed, one must ensure that only representative
tissue is subjected to hybridization to the microarray chips.
Contamination with leucocytes, neighboring blood vessels or
other normal tissue will contribute to the overall transcrip-
tomic profile. (2) If the goal of the analysis is to measure
therapeutic response to e.g. irradiation or cytotoxic drugs one
must sample tissue at first-time surgery as well as after
completed adjuvant therapy. Thus, the patient must undergo
repeated surgerywith the inherent risk factors. (3) RNA is very
susceptible to time dependent degradation due to abundant
RNase in the environment. Low quality RNA cannot be
subjected to microarray analysis. Hence, the personnel
involved in the sampling and handling of tissue must be
dedicated and have a proper logistic procedure in order to
preserve RNA. This means that tissue must be snap-frozen in
liquid nitrogen in the operating theater and then transferred to
permanent storage at ultra cold temperatures or in media
containing RNase inhibitors. 4) Since transcriptome analysis
can reveal genes that differ between tissue types, appropriate
controls and groups of e.g. tumors have to be selected long
before time of study. Asmeningiomas develop from arachnoid
cells [4], it follows that such cells should be selected if the
purpose was to find meningioma-specific genes. If dura or
whole brain were used as controls the transcriptional profile
would presumably be different due to the comparison of
different tissue types. It would thus be impossible to call
these genes different because of tumorigenesis per se. Only
one of the 13 studies states that arachnoid tissue has been
used as controls [21]. However, if the purpose is to identify
genes associated with the different WHO grades it follows
that no additional controls would be needed.
The main limitations of the studies were small sample
size and unequal group sizes when performing statistical
comparison. This illustrates how difficult it is to recruit
patients and controls to such studies. It may also be due to
the relatively high cost of performing microarray analysis.
Furthermore, the results of the studies have to be
functionally tested in order to safely identify biological
markers and key players in meningioma pathogenesis.
As in most microarray studies of the transcriptome, new
genes and pathways have been revealed in all the meningioma
studies. The challenge is to make use of the results clinically. At
present, microarray chip technology is mature and with low
technical error rate. Thus, the main issues that have to be
handled in transcriptomic projects are study design, represen-
tative tissue source, logistics, and data interpretation. Since
transcriptome analysis only provides snapshots of the gene
expression state in cells constituting the tissue at study, clear
improvements in diagnostic accuracy or clinical endpoints
(e.g., improved recurrence free survival) must be objectively
shown before the results of such studies can be safely
implemented in the clinical armamentarium. This notion is by
no means reserved for microarray studies, as all new methods
have to be quality checked accordingly before clinical approval.
Microarray studies have been taken into account for a trend
towards personalized medicine, e.g. the genetic profile of a
patient’s tumor could tell which pathways that could be
pharmacologically inhibited. However, as long as there are no
individually designed drugs, such treatment is reserved for the
future. How eager the pharmacological industry is to make such
designed drugs, which presumably are more expensive than
mass production, remains to be seen. Nevertheless, the
molecular technology is continuously developing new and
faster methods for the analysis of the nucleic acids. Next-
generation sequencing is already “this generation”; the first
people and cancers have been deciphered at base-pair resolution
by the so-called deep sequencing technology. The complete
sequencing of the human genome that took 10 years in the last
decade of the twentieth century can now be performed in a few
days. Therefore, awaiting individualized therapy, the era of the
personalized genome is inevitably about to begin.
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Comment
As a frequent reviewer for Acta, I have done my best to shoot down
reports of immunostaining of this or that protein in this or that tumor
as useless philately from by-gone decades.
At last—transcriptomic data on meningioma reviewed by the Norwe-
gian colleagues in the era of genomics/transcriptomics/signalomics/
metabolomics/glycomics/et al. mics (1–4). RNA sequencing of tran-
scriptome of target tissue—analysis of differential signaling pathways—
probing of synthetic molecules from drug libraries into key receptors—new
ideas for phase I–II clinical drug trials. Furthermore, with the techniques
cheaper, honed and widespread, each tumor in each carrier could be
individually profiled for optimal therapies and outcome—we hope.
Juha E Jääskeläinen
Kuopio, Finland
1. Aarhus M, Bruland O, Sætran HA, Mork SJ, Lund-Johansen M,
Knappskog PM. Global gene expression profiling and tissue micro-
array reveal novel candidate genes and down-regulation of the tumor
suppressor gene CAV1 in sporadic vestibular schwannomas. Neuro-
surgery 2010;67:998–1019
2. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen
M, Antti H, Bergenheim AT. Proteomic profiles differ between bone
invasive and noninvasive benign meningiomas of fibrous and
meningothelial subtype. J Neurooncol 2009;94:321–31
3. Aarhus M, Bruland O, Bredholt G, Lybaek H, Husebye ES,
Krossnes BK, Vedeler C, Wester K, Lund-Johansen M, Knappskog
PM. Microarray analysis reveals down-regulation of the tumor
suppressor gene WWOX and up-regulation of the oncogene TYMS
in intracranial sporadic meningiomas. J Neurooncol 2008;88:251–9
4. Kurki M, Häkkinen S-K, Frösen J, Tulamo R, von und zu
Fraunberg M, Wong G, Tromp G, Niemelä M, Hernesniemi J,
Jääskeläinen JE, Ylä-Herttuala S. Rupture of saccular intracranial
aneurysm wall associates to inflammation, leukocyte infiltration, oxida-
tive stress, extracellular matrix degradation, and apoptosis in gene
expression profiling. Neurosurgery (in press)
456 Acta Neurochir (2011) 153:447–456
